Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a prospective data collection study evaluating the feasibility of using the ChromoSeq® assay for upfront classification in a real-time clinical setting of pediatric and young patients suspected of having ALL. Sixty patients will undergo collections of bone marrow and/or peripheral blood for the ChromoSeq® assay at time of initial workup as part of standard of care, and the patients will then be followed for clinical outcomes for up to 65 months.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Dzieci i młodzi dorośli poniżej 30. roku życia leczeni w Szpitalu Dziecięcym św. Ludwika
- •Podejrzenie białaczki limfoblastycznej (ALL) typu B lub T, lub podejrzenie nawrotu choroby
- •Możliwość podpisania zgody na udział w badaniu przez pacjenta i/lub rodziców lub opiekunów prawnych
Simplified criteria — AI translation
Trial details
- Maximum age
- 30 Years
- Last updated (source)
- October 9, 2026
- Sex
- No restrictions
Locations (1)
Washington University School of Medicine/St. Louis Children's Hospital
St Louis, United States
Trial contact
Margaret Ferris, MD, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.